“Radiopeptides destroy tumor cells” film Youtube author: M. de Jong
PRRT is the abbreviation of Peptide Receptor Radionuclide Therapy. This therapy is used for patients with neuroendocrine tumors (NET). NET is a rare form of cancer. By administering the radioactive protein lutetium octreotate to the patient, it is possible to treat the tumors with precision. The quality of life of the patient improves with this treatment in many cases.
This treatment was developed in the PRRT Treatment Center in Rotterdam. On average we treat 8 patients with PRRT every week.
PRRT was developed by the PRRT Treatment Center Rotterdam. A reassuring thought.
PRRT and NET
NET is an abbreviation for Neuro-Endocrine Tumor. These tumors develop from the neuroendocrine cells that are present in every human body. In order to treat this form of cancer, we use Peptide Receptor Radionuclide Therapy (PRRT) at our treatment center.
The Peptide Receptor, located on the outside of the tumor cell, can bind peptides (=proteins). On neuroendocrine tumors (NETs) the peptide receptor is called the somatostatin receptor. It binds the body’s own protein somatostatin. For PRRT treatment we bind a radioactive particle (lutetium) to this protein. The somatostatin, with the lutetium attached to it, is then bound to the tumor cells by the receptor, and is thus transported inside. In this way, the radioactive lutetium octreotate can treat the tumor cell from the inside. This is a proven method which often has good results.
The patient can only be treated if he or she has had a positive OctreoScan preceding the treatment, and if he or she meets other specific requirements. A positive scan shows that the radioactively marked octreotide is incorporated well at the NET site and at possible metastases. A scan is therefore important, as it gives a good indication of the results.
At the PRRT Treatment Center in Rotterdam we treat around 100 patients every year, often with good results. The final result of the treatment is partially dependent on the number of somatostin receptors on the NET. A higher number of receptors lead to a higher intake through these receptors, and therefore to more radioactivity in the tumor.